Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

Summary

This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia. Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also, glycine will improve negative symptoms and cognitive deficits in schizophrenia.

Timeline

Start

2003-06

Primary completion

2015-12

Completion

2015-12

Drugs

Indications